HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 46, 33396-33404, November 16, 2007

This Article Abstract Full Text (PDF) Supplemental Data All Versions of this Article: 282/46/33396    most recent M705224200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwamoto, N. Articles by Kumagai, Y. Search for Related Content PubMed PubMed Citation Articles by Iwamoto, N. Articles by Kumagai, Y. Social Bookmarking                      What's this?

Chemical Knockdown of Protein-tyrosine Phosphatase 1B by 1,2-Naphthoquinone through Covalent Modification Causes Persistent Transactivation of Epidermal Growth Factor Receptor^*

Noriko Iwamoto, Daigo Sumi, Takeshi Ishii, Koji Uchida^¶, Arthur K. Cho^||, John R. Froines^||, and Yoshito Kumagai^||1

From the Doctoral Programs in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305-8575, Japan, the Department of Food and Nutritional Sciences and Global COE Program, University of Shizuoka, Shizuoka 422-8526, Japan, the ^¶Laboratory of Food and Biodynamics, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan, and the ^||Southern California Particle Center, Institute of the Environment, University of California, Los Angeles, California 90095

Received for publication, June 26, 2007 , and in revised form, September 10, 2007.

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
1,2-Naphthoquinone (1,2-NQ), an atmospheric contaminant, causes the contraction of guinea pig trachea through the activation of epidermal growth factor receptor (EGFR) by inhibiting protein-tyrosine phosphatases (PTPs). Phosphorylation of EGFR is negatively regulated by PTPs, but details of the mechanism by which 1,2-NQ inhibits PTPs have not been elucidated. Results described in this report demonstrate that 1,2-NQ forms covalent bonds with PTP1B after exposure to human epithelial A431 cells. In this study, a concentration-dependent phosphorylation of EGFR was found to be coupled to the reduction of PTP activity in the cells. The reduction in PTP activity was due to the irreversible modification of PTP1B, and when PTP1B was overexpressed by the cells, the 1,2-NQ-mediated EGFR phosphorylation was suppressed. Studies with purified PTP1B and 1,2-NQ showed that the reduction in enzyme activity was due to a nucleophilic attack by the quinone on the enzyme, to form covalent bonds. Matrix-assisted laser desorption and ionization time-of-flight mass spectrometry analysis and mutation experiments revealed that PTP1B inactivation was primarily due to covalent attachment of the quinone to Cys-121 of the enzyme, with binding to His-25 and Cys-215 as well. Collectively, the results show that covalent attachment of 1,2-NQ to PTP1B is at least partially responsible for the reduction of PTP activity, which leads to prolonged transactivation of EGFR in the cells.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Most intracellular signaling cascades are mediated by receptor tyrosine kinases, and the activated signals are transmitted to downstream proteins by sequential phosphorylation. Because protein tyrosine phosphorylation is negatively regulated by protein-tyrosine phosphatases (PTPs), ² these dephosphorylation enzymes play important roles in the signal transduction controlled by receptor tyrosine kinases. PTPs are a diverse family of enzymes that can be divided into several subgroups, including receptor PTPs and non-receptor PTPs. All PTPs contain an essential cysteine residue in the active site motif, HCX₅R(S/T) (1). This sulfhydryl group, as thiolate anion, contributes to the formation of a thiol-phosphate intermediate in the dephosphorylation reaction and is therefore essential for enzyme activity (2). Because of the low pK_a of the catalytic cysteine (e.g. 5.4 for mammalian PTPs) (3), PTP thiols are readily oxidized to their sulfenic acid (-SOH) state by reactive oxygen species (ROS) (4, 5), thereby decreasing dephosphorylation activity. Current consensus is that PTP activity is regulated by endogenous oxidant such as hydrogen peroxide (H₂O₂) in cells (6, 7). The decreased PTP activity associated with epidermal growth factor receptor (EGFR) activation caused by H₂O₂ is transient and restored by cellular reduction systems (8). However, if reactive thiols of PTPs undergo covalent modification by exogenous electrophiles, irreversible inactivation of PTPs, resulting in prolonged phosphorylation of EGFR, would occur.

We have been examining the reactivity and toxicology of selected quinones (9–13) in an effort to establish mechanistic pathways that may account for the adverse health effects associated with exposure to mixtures in which they are present. Quinones, including 1,2-NQ of this study, have been found at significant concentrations in vehicle exhaust particles and in ambient air samples (14–16), so their toxic actions have considerable relevance to understanding air pollution toxicity. Quinones are a class of organic compounds that undergo two toxicologically relevant reactions (9, 17, 18). One is as an electrophile, forming covalent bonds with tissue nucleophiles to irreversibly alter key cellular proteins. In the second reaction the quinone acts as an electron transfer agent, transferring electrons from a reducing source such as NADPH to oxygen, generating ROS such as H₂O₂.

We recently reported that 1,2-NQ elicits a contraction of smooth muscle in guinea pig tracheal preparations under conditions that indicated transactivation of EGFR was involved in the contraction process (19). These studies also suggested that 1,2-NQ-induced EGFR activation was caused, at least partially, by covalent modification and/or thiol oxidation of PTP1B, leading to the reduction of its dephosphorylation activity. Of the multiple PTPs, PTP1B is ubiquitously expressed (20) and negatively regulates receptor tyrosine kinases such as EGFR (21), so that inhibition of this PTP would lead to EGFR activation. Although 1,2- and 1,4-NQ and their derivatives are reported to be potent inhibitors for PTP1B (22, 23), their detailed mechanism of action still remains unclear. This report describes results of a study of 1,2-NQ-PTP1B interaction, which demonstrates that 1,2-NQ-mediated covalent modification of PTP1B, accompanied by reduction of its enzyme activity, results in the transactivation of EGFR in human epithelial A431 cells. The results also show that arylation of PTP1B through Cys-121 is the predominant event in the loss of enzyme activity caused by 1,2-NQ.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Materials—1,2-NQ was purchased from Tokyo Kasei Industries, Ltd. (Tokyo, Japan). Naphthalene, Dulbecco's modified Eagle's medium, penicillin streptomycin solution, imidazole, p-nitrophenol (pNP), and 3,5-dimethoxy-4-hydroxycinnamic acid were obtained from Sigma. trans-1,2-Dihydroxy-1,2-dihydronaphthalene was kindly donated by Dr. S. Yamano (Fukuoka University, Japan). 5, 5'-Dithiobis(2-nitrobenzoic acid) (DTNB) and isopropyl-1-thio--D-galactopyranoside were purchased from Nacalai Tesque (Kyoto, Japan). p-Nitrophenyl phosphate (pNPP) was purchased from ICN Biomedicals (Irvine, CA). Escherichia coli BL21 cells and sequence grade modified trypsin were purchased from Promega (Madison, WI). Gluta Max-1, fetal bovine serum, Opti-MEM medium and pcDNA3.1/HisC were obtained from Invitrogen. FuGENE HD transfection reagent was purchased from Roche Applied Science. -Cyano-4-hydroxycinnamic acid was purchased from Bruker Daltonics Japan (Tokyo, Japan). pET15b was purchased from Novagen (Madison, WI). EGFR-neutralizing antibody LA-1 was purchased from Upstate (Lake Placid, NY). All other reagents used were of the highest purity available.

Preparation of Anti-1,2-NQ—The polyclonal antibody against 1,2-NQ was prepared by a modification of the method of Zheng and Hammock (24). Water-soluble keyhole limpet hemocyanin (KLH, 20 mg) was dissolved in 3.5 ml of 4 M guanidinium chloride, followed by addition of 20 mg of dithiothreitol (DTT) to reduce oxidized thiol groups of the KLH. The mixture was stirred under argon at room temperature in the dark for 2 h. The reduced proteins were loaded to an Econo-Pac 10 DG column (Bio-Rad), which had been equilibrated with 50 mM potassium phosphate buffer (pH 7.0), 0.1 mM EDTA to remove DTT. Then the KLH solution (equivalent to 10 mg) was mixed with 1,2-NQ (1 mg dissolved in Me₂SO) under argon at 25 °C for 20 min, and the mixture was dialyzed against the equilibrated buffer described above. The binding efficiency of 1,2-NQ to KLH was measured using a Shimadzu high-performance liquid chromatography system (Kyoto, Japan). An aliquot (40 µl) of the reaction mixture was applied to an AM-type YMC-ODS column (250 x 4.6-mm inner diameter, 5-µm particle size, Yamamura Labs, Kyoto, Japan), at a flow rate of 1 ml/min. Water/acetonitrile (3:2, v/v) was used as the mobile phase, and detection was performed at 255 nm. Under these conditions, the retention time of 1,2-NQ was 7.9 min. Final preparation of KLH-1,2-NQ adduct was 0.33 mg of 1,2-NQ bound per milligram of KLH. Antibodies against 1,2-NQ were raised in male New Zealand White rabbits. The IgG fraction was isolated from the serum obtained according to previously described methods (25).

Cell Culture and Transfection—Human epidermoid carcinoma cell line A431 cells (ATCC, Manassas, VA) were grown at 37 °C in a humidified atmosphere containing 5% CO₂ in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM Gluta Max-1 and antibiotics (100 units/ml penicillin, 100 µg/ml streptomycin). A431 cells were grown to 70% confluency on 35-mm plates. Transfection was performed with FuGENE HD transfection reagent according to manufacturer's instructions. A431 cells were transfected with lacZ (pcDNA/His-lacZ) or PTP1B (pcDNA/His-PTP1B) for 48 h.

Western Blotting—Cells were extracted with radioimmune precipitation assay lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% deoxycholate, 0.1% SDS, 1 mM EGTA, 0.4 mM EDTA, and protease inhibitor mixture. Each sample was normalized to a protein content of 20 µg then mixed with half the volume of SDS-PAGE loading buffer consisting of 62.5 mM Tris-HCl (pH 6.8), 24% glycerol, 6% SDS, 15% 2-mercaptoethanol, and 0.015% bromphenol blue. The samples were heated at 95 °C for 1 min and were separated by SDS-PAGE (7.5 or 12% acrylamide) (26). Electrophoresed proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad). Blots were blocked for 12 h with 5% skim milk in TTBS (20 mM Tris (pH 7.5), 150 mM NaCl, 1% Tween 20), washed briefly and incubated with the indicated primary antibodies. Anti-EGFR (Upstate, Lake Placid, NY), anti-phospho EGFR that recognized Tyr-1068 (Sigma), anti-PTP1B (see below), and anti-1,2-NQ were used as primary antibodies. HRP-conjugated rabbit anti-sheep that recognized anti-phospho EGFR, HRP-conjugated goat anti-rabbit, and HRP-conjugated horse anti-mouse (Cell Signaling Technology, Beverly, MA) were used as secondary antibodies.

For immunoprecipitation studies, cell lysates were incubated with Affi-gel 10 (Bio-Rad) cross-linked with anti-37-kDa PTP1B IgG (8.2 mg of protein/ml of gel) which was prepared according to the manufacturer's instructions. The gels were centrifuged at 13,000 x g for 1 min and then washed with 1 ml of ice-cold radioimmune precipitation assay lysis buffer three times, and the PTP1B from the cell lysates was eluted with 20 µl of 0.1 M glycine-HCl (pH 3.0) at 25 °C. Proteins were detected by immunoblot analysis as described above. Protein bands on the membrane were detected by using chemiluminescence reagents and film according to the manufacturer's instructions (GE Healthcare Bio-Sciences Corp.) and exposed on high-performance chemiluminescence film (GE Healthcare Bio-Sciences Corp.) (27). Data for Western blotting are representative of three or more experiments. Protein concentration was determined with the Bio-Rad Protein assay kit (28) or the BCA protein assay reagent (Pierce), with bovine serum albumin as a standard.

Mutagenesis and Protein Expression—Complementary DNA, corresponding to the 37-kDa form (NH₂-terminal 321 residues) of PTP1B, was obtained by PCR, placed downstream of the phage T7 RNA polymerase promoter at the NdeI site of pET15b. A plasmid containing the isolated catalytic domain of human 37-kDa PTP1B in a pET15b vector was used as a template for site-directed mutagenesis. Cys-to-Ser and His-to-Ala mutations were introduced using a PCR-based approach following established procedures (29). The resulting construct was verified by DNA sequencing on an ABI 310 DNA sequencer (Applied Biosystems, Foster City, CA). The resulting plasmid was transformed into E. coli BL21 cells for protein expression. The bacterial cultures were grown in LB broth at 37 °C with shaking at 120 rpm (TAITEC, Saitama, Japan) to 0.6 absorbance units at 600 nm. The cultures were then induced by the addition of 0.2 mM isopropyl-1-thio--D-galactopyranoside and grown for an additional 20 h. The cells were harvested by centrifugation, and the cell lysates were analyzed by electrophoresis and immunoblotting using the protocol outlined above.

Purification of 37-kDa PTP1B and Its Mutants—All steps during purification were performed at 4 °C. E. coli BL21 cells transformed with the expression vector were suspended in lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 0.1 mM NaCl, 10 mM 2-mercaptoethanol, and 10% glycerol. The supernatant was retained following centrifugation at 100,000 x g for 1 h of the sonicated-cell lysates, and then applied to a Ni-IDA ProBond (Invitrogen) column (4 x 1 cm inner diameter), which had been equilibrated with 50 mM Tris-HCl (pH 7.5), 0.1 mM NaCl, 10 mM 2-mercaptoethanol solution. The affinity column was extensively washed with the equilibrated buffer, and then 37-kDa PTP1B and its mutants were eluted with the buffer containing 100 mM imidazole. The purity of the PTP1B preparations, as assessed by SDS-PAGE, was >90%. Thiol groups oxidized during purification were reduced by incubation with 20 mM DTT for 1 h, and the DTT was removed by an Econo-Pac 10 DG column. Each enzyme preparation was stored in 50 mM potassium phosphate buffer (pH 7.0) at–80 °C before use. The polyclonal antibody against 37-kDa PTP1B was prepared by the same method used for anti-1,2-NQ.

Dephosphorylation Activity—Cultured cells were treated with different concentrations of 1,2-NQ for 10 min. Then, the medium was removed, and cell radioimmune precipitation assay lysis buffer was added to the culture dish. The cell extracts were scraped from the dish and transferred to microcentrifuge tubes. Supernatants obtained from centrifugation at 13,000 x g for 10 min were used for phosphatase assays.

Phosphatase Assay—Briefly, cell lysate (100 µg) was incubated with 4 mM pNPP and 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, bovine serum albumin (0.1 mg/ml). The reaction was allowed to proceed for 20 min at 37 °C and terminated by addition of 1.8 ml of 1 M NaOH. The pNP formed was determined at 400 nm using a Hitachi U-1500 spectrophotometer (Tokyo, Japan).

A two-stage incubation method was employed to monitor the effect of 1,2-NQ on PTP1B activity. The incubation mixture (0.2 ml) for the first stage consisted of 37-kDa PTP1B (0.1 mg), different concentrations of 1,2-NQ and 50 mM potassium phosphate buffer (pH 7.5), 0.1 mM EDTA, unless other noted. Reactions were initiated by addition of 1,2-NQ. After incubation at 25 °C for various times, aliquots (1 µl) were transferred to the second incubation mixture (1 ml) to determine PTP1B activity. The second incubation reaction mixture consisted of the aliquot, 4 mM pNPP, 100 mM acetate buffer (pH 5.5), and 0.1 mM EDTA. Incubations were carried out at 25 °C for 10 min and terminated by addition of NaOH to make a final concentration of 1 M. Under these conditions, dephosphorylation of pNPP was linear with time and protein concentration.

Determination of Free SH Groups—PTP1B was incubated at 25 °C with 50 µM 1,2-NQ in a total volume of 200 µl containing 50 mM potassium phosphate buffer (pH 7.5). After 10 min, the reaction was stopped by adding 300 µl of 200 mM Tris-HCl (pH 8.2), 20 mM EDTA. The reaction mixture and control untreated enzymes were mixed with solution containing 20 µl of 10 mM DTNB, 150 µl of 5% SDS, and 830 µl of H₂O. After 2 min, the concentration of thionitrobenzoic acid released was determined spectrophotometrically using a molar extinction coefficient of 13,600 at 412 nm (30).

Matrix-assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry (MALDI-TOF MS)—PTP1B was incubated with 0 or 50 µM 1,2-NQ for 10 min at 25 °C in a buffer containing 50 mM potassium phosphate buffer (pH 7.5) and then dialyzed into 50 mM potassium phosphate buffer (pH 7.0) using an Econo-Pac 10 DG column to remove free 1,2-NQ. The trypsin-digested PTP1B were mixed with DTT and trifluoroacetic acid. To improve the ionization efficiency of mass spectrometry, samples were purified with Zip-tip C4 or C18 (Millipore, Bed-ford, MA) before MS and MS/MS analysis. Peptides were mixed with -cyano-4-hydroxycinnamic acid (2.5 mg/ml) containing 50% acetonitrile and 0.1% trifluoroacetic acid and dried on stainless steel targets at room temperature and pressure. The analyses were performed using an Ultraflex MALDI-TOF mass spectrometer (Bruker Daltonics Japan, Ltd., Tokyo) with a nitrogen laser. All analyses were in the positive ion mode, and the instrument was calibrated immediately prior to each series of studies.

Data Analysis—All data were expressed as means ± S.E. from at least three independent experiments. Statistical significance was considered at p < 0.05. Data were fitted by nonlinear regression analysis according to a Michaelis-Menten kinetic model (GraphPad Prism version 4.0, San Diego, CA).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 
Phosphorylation of EGFR Coupled to Reduction of PTP Activity by 1,2-NQ in the Cellular System—Exposure of A431 cells to 1,2-NQ for 10 min caused a concentration-dependent phosphorylation of EGFR (Fig. 1A). Under these conditions, 1,2-NQ also inhibited cellular PTP activity in a concentration-dependent manner, but the reduction of PTP activity by 1,2-NQ reached a plateau at 50 µM (Fig. 1A). To examine whether or not 1,2-NQ-induced EGFR phosphorylation is ligand-dependent, we pretreated the cells with a EGFR-neutralizing antibody LA-1 for EGFR prior to exposure of A431 cells to 1,2-NQ. As shown in Fig. 1B, A431 cells subjected to the EGFR-neutralizing antibody LA-1 exhibited a complete inhibition of EGF-induced EGFR phosphorylation, whereas only a slight suppression of 1,2-NQ-induced EGFR phosphorylation was detected. These results suggested that a ligand-independent EGFR phosphorylation through the inhibition of PTP activity occurs during exposure of A431 cells to 1,2-NQ. In temporal experiments conducted over 720 min, EGFR phosphorylation by EGF in A431 cells was seen up to 180 min, after which it declined (Fig. 1C). In contrast, EGFR activation caused by 1,2-NQ was persistent even at 720 min but with a biphasic transactivation of EGFR phosphorylation (see Fig. 1C). Because PTP inactivation by 1,2-NQ could be due to either thiolate oxidation or arylation, we examined the effect of ROS-scavenging agents on the transactivation. H₂O₂-mediated phosphorylation of EGFR was blocked by pretreatment of A431 cells with either catalase conjugated with polyethylene glycol or Trolox, a scavenging agent for ROS, whereas EGFR activation caused by 1,2-NQ was not (supplemental Fig. S1). These results suggest that such a prolonged phosphorylation of EGFR during exposure of A431 cells to 1,2-NQ was not due to thiol oxidation and could be due to covalent binding of this quinone to cellular PTPs.

View larger version (36K): [in this window] [in a new window]   FIGURE 1. EGFR phosphorylation and reduction of PTP activity during exposure of A431 cells to 1,2-NQ. A, concentration-dependent activation of EGFR (top) and alteration in PTP activity (bottom). A431 cells were grown to 80–100% confluency and serum-starved overnight and then exposed to 1,2-NQ (0–100 µM) for 10 min. The cell lysates were examined by Western blotting using an anti-phospho EGFR (Tyr-1068) antibody. PTP activity in the cell lysates was determined with pNPP as a substrate under the conditions as described under "Experimental Procedures." Data are means ± S.E. of three independent experiments and are expressed as a percentage of the initial activity. * and ** indicate data significantly different from 1,2-NQ-treated, uninhibited conditions at p < 0.05 and p < 0.01, respectively. B, A431 cells were pretreated with 1 µg/ml of the EGFR-neutralizing antibody LA-1 for 1 h. The cells were then exposed to EGF for 30 min or 1,2-NQ for 10 min. C, a time-dependent activation of EGFR during exposure to EGF (top) or 1,2-NQ (bottom). A431 cells were exposed to EGF (5 ng/ml) or 1,2-NQ (20 µM) for the indicated times. Then, whole the cell lysates were used for Western blotting with anti-phospho-EGFR (Tyr-1068) or anti-EGFR.

Involvement of Covalent Binding of 1,2-NQ in Decreased 37-kDa PTP1B Activity—As shown in Fig. 3A, 37-kDa PTP1B activity was inhibited by 1,2-NQ in a time- and concentration-dependent manner. The apparent first order decay rates were linear with concentration with a slope of 0.014 µM –1 min^–1. When fixed concentrations of 1,2-NQ were incubated with PTP1B for 10 min, the reduction of PTP1B activity caused by 1,2-NQ paralleled the increase in covalent modification of this quinone to PTP1B (Fig. 3B). H₂O₂ is reported to inhibit PTP1B activity through the oxidation of Cys-215 presumably to the corresponding sulfenic acid (7), but the decreased PTP1B activity was readily restored by addition of 4 mM DTT through reduction of the oxidized thiol groups (Fig. 3C). However, DTT had no effect on the loss of PTP1B activity caused by 1,2-NQ (Fig. 3C), supporting the notion that an irreversible or covalent bond-based inactivation rather than thiol oxidation of 1,2-NQ is occurring.

To further characterize the covalent modification of PTP1B by 1,2-NQ, we compared 1,2-NQ with the other naphthalene derivatives shown in Fig. 4A. In earlier studies we observed guinea pig tracheal contraction caused by 1,2-NQ by EGFR phosphorylation, whereas trans-1,2-dihydroxy-1,2-dihydronaphthalene and naphthalene (see Fig. 4A) were without effect on the contractile action and activation of EGFR (19). This suggests an obligatory role of an electrophilic function in the contraction of guinea pig trachea. As shown in Fig. 4B, the extent of covalent binding of 1,2-NQ (5 and 50 µM) increased with a corresponding reduction of 37-kDa PTP1B activity. However, trans-1,2-dihydroxy-1,2-dihydronaphthalene and naphthalene, which are incapable of binding to PTP1B, did not exhibit any inhibitory action on PTP1B (Fig. 4B). These results indicate that the decreased PTP1B activity was dependent on the electrophilic property of 1,2-NQ.

View larger version (41K): [in this window] [in a new window]   FIGURE 2. Blockage of 1,2-NQ-mediated phosphorylation of EGFR by overexpression of PTP1B (A) and covalent binding of 1,2-NQ to cellular PTP1B during exposure of A431 cells to 1,2-NQ (B). A, pcDNA/His-PTP1B was transfected into A431 cells. The cells were then treated with 1,2-NQ (20 µM) for 10 min, and whole cell lysates were used for Western blotting with anti-phospho EGFR (Tyr-1068), EGFR, or PTP1B. B, the cells were exposed to 1,2-NQ (100 µM) for 10 min. Immunoprecipitation of PTP1B from the whole cell lysates was performed by using Affi-gel 10 cross-linked with anti-PTP1B. Then, covalent binding of 1,2-NQ to cellular PTP1B was detected with the same sample by Western blotting with anti-1,2-NQ.

MALDI-TOF MS Analysis of Arylated 37-kDa PTP1B—To determine the modification sites in 1,2-NQ, the native and 1,2-NQ-treated PTP1B were digested with trypsin and then analyzed by MALDI-TOF MS. Peptide mass mapping by MALDI-TOF MS analysis of the tryptic fragments from the native PTP1B accounted for 70% of the protein sequence (Fig. 5 and Table 1). Compared with the calculated mass of the unmodified peptides, modified peptides P-1 to P-4, showed an increased mass of +156 Da, corresponding to the addition of a single equivalent of 1,2-NQ. The peptides, their sequence and masses are: P-1 (CAQYWPQK, m/z = 1179.6), P-2 (HEASDFPCR, m/z = 1217.6), P-3 (GSLKCAQYWPQK, m/z = 1564.6), and P-4 (ESGSLSPEHGPVVVHCSAGIGR, m/z = 2330.1) (Fig. 5 and Table 1). These peptides were also detected in the selective ion monitoring analysis of tryptic peptides from the 1,2-NQ-treated PTP1B using electrospray ionization-liquid chromatography-MS (supplemental Fig. S2). No other peptides with 1,2-NQ adducts were detected by selective ion monitoring analysis.

View larger version (24K): [in this window] [in a new window]   FIGURE 3. Inhibition of recombinant 37-kDa PTP1B activity by irreversible modification of 1,2-NQ. A, decreased PTP1B activity caused by 1,2-NQ. Recombinant 37-kDa PTP1B (0.1 mg) was incubated at 25 °C in the absence () or presence of 2.5 µM (), 5 µM (), 10 µM (), 15 µM (•), 20 µM (), 30 µM (), and 50 µM () 1,2-NQ in a total volume of 200 µl containing 50 mM potassium phosphate buffer (pH 7.0). At the indicated times, 1 µl of the reaction mixture was transferred to a sample tube, and then dephosphorylation activity of PTP1B was determined with pNPP as a substrate. Control dephosphorylation activity of 37-kDa PTP1B was 51.7 ± 3.2 µmol of pNP formed/min/mg. B, covalent attachment of 37-kDa PTP1B to 1,2-NQ. Recombinant 37-kDa PTP1B (0.1 mg) was incubated at 25 °C in a total volume of 200 µl containing 50 mM potassium phosphate buffer (pH 7.0) and the indicated concentrations of 1,2-NQ. After incubation was carried out for 10 min, covalent modification of 1,2-NQ to 37-kDa PTP1B was evaluated by Western blotting with anti-1,2-NQ or PTP1B. C, effects of DTT (4 mM) on decreased PTP1B activity during reaction with H2O2 and 1,2-NQ at a concentration of 50 µM. After interaction of 37-kDa PTP1B with either 1,2-NQ or H2O2, each reaction mixture was incubated with DTT for 1 h. Then, PTP1B activity was determined. Data are means ± S.E. from three independent experiments and are expressed as a percentage of the initial activity.

View larger version (23K): [in this window] [in a new window]   FIGURE 4. Obligatory role of quinone function in the decreased 37-kDa PTP1B activity. A, 1,2-NQ, 1,2-naphthoquinone; DDN, trans-1,2-dihydroxy-1,2-dihydronaphthalene; and N, naphthalene. B, 37-kDa PTP1B (0.1 mg) was incubated at 25 °C for 10 min in the absence or presence of each compound (5 or 50 µM) in a total volume of 200 µl containing 50 mM potassium phosphate buffer (pH 7.0). Covalent attachment to 37-kDa PTP1B was determined by Western blotting with anti-1,2-NQ or PTP1B (top), and PTP1B activity was assayed with pNPP as a substrate (bottom). **, data significantly different from 1,2-NQ-treated, uninhibited conditions at p < 0.01.

The MS/MS spectrum of the [M + H]⁺ at m/z = 1217.4 from the 1,2-NQ-modified fragment (P-2, HEASDFPCR) is shown in Fig. 6B. The singly charged C-terminal product ions (y1, y3, y4, y5, y6, y7, and y8) and the NH₃-lost product ion (y3-17) were observed in the MS/MS analysis. Fragment ions (b2, b3, b4, b5, b6, b7, and b8) were observed to have increased by 156 Da. Furthermore, immonium and related ions (His, 110.1 and 138.1) were shown to increase by 156 Da. These results confirmed that the 1,2-NQ Michael adduct is with His-25. Furthermore it was confirmed by electrospray ionization-liquid chromatography-MS/MS analysis (supplemental Fig. S3). In this manner, we identified the two target residues as His-25 and Cys-121.

If the covalent modification of Cys-121 and His-25 of 37-kDa PTP1B is involved in the reduction of its dephosphorylation activity, substitution of these nucleophilic amino acids with those that are incapable of reacting with 1,2-NQ should prevent the observed loss of catalytic activity caused by this quinone. To confirm this possibility, mutations of Cys-121 and Cys-215 to Ser (C121S and C215S) and His-25 to Ala (H25A) were performed. Dephosphorylation activities of wild type, C121S, and H25A of 37-kDa PTP1B were 51.7, 48.5, and 51.9 units/mg of protein, respectively, suggesting that these amino acid residues themselves do not affect PTP1B activity. However, substitution of Ser-121 for Cys-121, but not substitution of Ala-25 for His-25, prevented the decrease in PTP1B activity caused by 1,2-NQ (50 µM) (Fig. 7A). Consistent with this observation, covalent binding of 1,2-NQ to the wild-type PTP1B was lower after mutation of Cys-121 to Ser, but only slightly lower after mutation of His-25 to Ala (Fig. 7B). It should also be noted that there was a reduction of covalent binding of 1,2-NQ to PTP1B with substitution of Ser-215 for Cys-215, suggesting that not only Cys-121 and His-25 but also Cys-215 undergo irreversible modification by 1,2-NQ under the conditions.

View larger version (21K): [in this window] [in a new window]   FIGURE 5. MS analysis of peptides from 37-kDa PTP1B digested with trypsin following incubation with or without 1,2-NQ. The PTP1B was incubated at 25 °C for 10 min in the absence (bottom) or presence (top) of 50 µM 1,2-NQ in a total volume of 200 µl containing 50 mM potassium phosphate buffer (pH 7.0). After reaction, unreacted 1,2-NQ was removed by an Econo-Pac 10DG column with 50 mM potassium phosphate buffer (pH 7.5).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

View larger version (26K): [in this window] [in a new window]   FIGURE 6. Identification of modification sites of 37-kDa PTP1B by 1,2-NQ by MALDI-TOF-TOF MS analysis. A, the spectrum of the [M + H]+ ion at m/z from the 1,2-NQ-modified fragment (P-1) with the sequence CAQYWPQK. B, the spectrum of the [M + H]+ ion at m/z from the 1,2-NQ-modified fragment (P-2) with the sequence HEASDFPCR.

View larger version (33K): [in this window] [in a new window]   FIGURE 7. Effects of mutation of amino acids modified by 1,2-NQ on its enzyme activity (A) and covalent binding to 37-kDa PTP1B (B). PTP1B (WT) and its mutants (H25A, C121S, and C215S) were incubated with 50 µM 1,2-NQ at 25 °C for 10 min. PTP1B activity was assayed with pNPP. 1,2-NQ-binding protein was recognized by anti-1,2-NQ. Data are means ± S.E. from three independent experiments and are expressed as a percentage of the initial activity. **, p < 0.01 compared with WT.

The PTP superfamily is characterized by a highly conserved active site sequence motif referred to as HCX₅R(S/T) (1) in which the environment surrounding the cysteinyl thiol reduces the pK_a by several orders of magnitude. The pK_a value of the active thiol (Cys-215) in PTP1B is reported to be 5.4 (3), indicating that the cysteine thiol is highly ionized at physiological pH and likely initiates hydrolysis of phosphotyrosyl esters through a nucleophilic attack to form a cysteine-phosphate intermediate. The enhanced reactivity resulting from the low pK_a also makes the active site cysteine a target for covalent or oxidative modification. With this reactivity in mind, we determined the stoichiometry of 1,2-NQ bound to 37-kDa PTP1B from the thiol consumption following 1,2-NQ bonding. The results showed that approximately two equivalents of thiolate ions in the protein underwent covalent modification (data not shown). The arylation sites of 37-kDa PTP1B, identified by MALDI-TOF-TOF MS procedures (Fig. 6), were the Cys-121 and His-25 residues. Subsequent site-directed mutagenesis studies (Fig. 7) indicated that the arylation at Cys-121 was more important to the catalytic activity than that at His-25. Mutagenesis of Cys-121 to Ser showed repression of PTP1B inhibition with reduction in 1,2-NQ binding during 1,2-NQ exposure, whereas little appreciable change of decreased PTP1B activity caused by 1,2-NQ was seen in case of substitution of Ala-25 for His-25. We therefore conclude that Cys-121, but not Cys-215, in 37-kDa PTP1B is a highly nucleophilic group available for covalent attachment by 1,2-NQ, thereby causing substantial reduction of dephosphorylation activity.

Hansen et al. (33) reported previously that Cys-121, a nonactive site cysteine residue, is the site of allosteric inhibition of PTP1B activity. This cysteine residue is only 8.1 Å from the catalytic Cys-215 (34) (distance between C atoms), and the sulfur atom packs against the side chain of Tyr-124, which in turn forms a hydrogen bond with His-214, the residue preceding the active site Cys-215. Attachment of the 1,2-NQ structure to Cys-121 would disrupt this delicate packing arrangement, thereby perturbing the active site. Although we could not detect covalent modification of Cys-215 by 1,2-NQ binding in MS/MS analysis in the present study, such a similar result was also observed by MALDI-TOF-TOF MS (Fig. 4) and electrospray ionization-liquid chromatography-MS/MS (data not shown) analyses of the P-4 fragment. Nevertheless, our findings, 1) that the P-4 fragment obtained following digestion of 37-kDa PTP1B incubated with 1,2-NQ contained Cys-215 and 2) that mutation of C215S reduced covalent binding of 1,2-NQ to PTP1B, suggest that Cys-215 is also a target for 1,2-NQ. A reasonable explanation for our inability to detect Cys-215 attachment is that the high energy used in MS/MS analysis may have cleaved the C–S bond of the Cys-215 ·1,2-NQ complex. There are a number of PTPs in which Cys-121 (90%) and Cys-215 (100%) are highly conserved (34).

In this study, we also found that persistent transactivation of EGFR coupled to reduction of PTP activity during exposure of A431 cells to 1,2-NQ was biphasic (Fig. 1C), i.e. following 1,2-NQ exposure EGFR activation reached a maximal level at 30 min then declined to a minimum at 180 min followed by an increase over the next several hours. We speculate that not only PTP1B but other PTPs also undergo covalent modification at Cys-121 and/or Cys-215 by 1,2-NQ, leading to the accumulation of phosphorylated EGFR even at 720 min after 1,2-NQ exposure. As shown in Fig. 7, substitution of Ser-121 for Cys-121 caused a complete abolishment of decreased PTP1B activity caused by 1,2-NQ at 5 µM. At 50 µM 1,2-NQ, however, about only 50% of the loss of PTP1B caused by 1,2-NQ was restored by mutation of Cys-121. Taken together, we suggest that the specificity of thiol modification in PTP1B during reaction with 1,2-NQ exhibits a concentration dependence such that, at 5 µM, Cys-121 arylation is much faster than that of Cys-215, whereas at 50 µM the rates approach each other.

In other studies, 1,2-NQ has been shown to cause the contraction of tracheal smooth muscle in the same concentration range, through activation of the EGFR system (19) leading ultimately to stimulation of the vanillin receptor to cause smooth muscle contraction. In vivo experiments in which 1,2-NQ was intratracheally administered to ovalbumin-sensitized mice resulted in enhanced airway sensitivity and goblet cell hyperplasia, two actions that may indicate airway hyper-responsiveness that is associated with lung disease (12). Because these tissue and whole animal responses are occurring at comparable concentrations, it appears likely that the in vivo effects are mediated by initial inactivation of PTP1B.

The present study reports, for the first time, that chemical knockdown of PTP1B occurs by Michael addition of 1,2-NQ to the His-25, Cys-121, and Cys-215 residues. This reaction is irreversible so that recovery of PTP1B function in dephosphorylation of phosphorylated EGFR requires PTP1B resynthesis. Thus, the rate of recovery will depend on the turnover rate of the protein. If the rate is slow, chronic exposure to low concentrations of compounds like 1,2-NQ will have a cumulative effect on PTP activity in the cell. The EGFR has been demonstrated to play a key role in bronchial epithelial repair, remodeling, and control of airway inflammation (35), and effects on this system by environmental agents could be relevant to their known effects on airway diseases. Samet et al. (36) reported previously that exposure of airway epithelial cells to the ambient particulate matter cause a significant transactivation of EGFR. They subsequently showed that contaminating metals are capable of phosphorylating EGFR through a ligand-independent mechanism. The work reported here indicates that electrophiles such as 1,2-NQ, which are present in ambient particulate matter, can cause long term effects on the EGFR system and may contribute to the adverse health effects associated with airborne pollutants.

	FOOTNOTES

 
^* This work was supported by the Ministry of Education, Science, Culture and Sports of Japan (Grants-in-Aid 18659167 and 18406003 for scientific research to Y. K.) and by U. S. Environmental Protection Agency-funded Southern California Particle Center Grant RD83241301 (to J. R. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S3.

¹ To whom correspondence should be addressed. Tel.: 81-29-853-3133; Fax: 81-29-853-3133; E-mail: yk-em-tu{at}md.tsukuba.ac.jp.

² The abbreviations used are: PTP, protein-tyrosine phosphatase; 1,2-NQ, 1,2-naphthoquinone; PTP1B, protein-tyrosine phosphatase 1B; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ROS, reactive oxygen species; DTT, dithiothreitol; HRP, horseradish peroxidase; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); TBS, Tris-buffered saline; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MS, mass spectrometry; MS/MS, tandem mass spectrometry; pNP, p-nitrophenol; pNPP, p-nitrophenol phosphate; KLH, keyhole limpet hemocyanin.

	ACKNOWLEDGMENTS

 
We greatly appreciate the gift of trans-1,2-dihydroxy-1,2-dihydronaphthalene from Dr. Shigeru Yamano (Fukuoka University, Japan).

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

 

1. Zhang, Z. Y. (2002) Annu. Rev. Pharmacol. Toxicol. 42, 209–234[CrossRef][Medline] [Order article via Infotrieve]
2. Barford, D., Jia, Z., and Tonks, N. K. (1995) Nat. Struct. Biol. 2, 1043–1053[CrossRef][Medline] [Order article via Infotrieve]
3. Lohse, D. L., Denu, J. M., Santoro, N., and Dixon, J. E. (1997) Biochemistry 36, 4568–4575[CrossRef][Medline] [Order article via Infotrieve]
4. Claiborne, A., Yeh, J. I., Mallett, T. C., Luba, J., Crane, E. J., 3rd, Charrier, V., and Parsonage, D. (1999) Biochemistry 38, 15407–15416[CrossRef][Medline] [Order article via Infotrieve]
5. Barrett, W. C., DeGnore, J. P., Keng, Y. F., Zhang, Z. Y., Yim, M. B., and Chock, P. B. (1999) J. Biol. Chem. 274, 34543–34546[Abstract/Free Full Text]
6. Caselli, A., Marzocchini, R., Camici, G., Manao, G., Moneti, G., Pieraccini, G., and Ramponi, G. (1998) J. Biol. Chem. 273, 32554–32560[Abstract/Free Full Text]
7. Lee, S. R., Kwon, K. S., Kim, S. R., and Rhee, S. G. (1998) J. Biol. Chem. 273, 15366–15372[Abstract/Free Full Text]
8. Tonks, N. K. (2003) FEBS Lett. 546, 140–148[CrossRef][Medline] [Order article via Infotrieve]
9. Kumagai, Y., Koide, S., Taguchi, K., Endo, A., Nakai, Y., Yoshikawa, T., and Shimojo, N. (2002) Chem. Res. Toxicol. 15, 483–489[CrossRef][Medline] [Order article via Infotrieve]
10. Kumagai, Y., Hayashi, T., Miyauchi, T., Endo, A., Iguchi, A., Kiriya-Sakai, M., Sakai, S., Yuki, K., Kikushima, M., and Shimojo, N. (2001) Am. J. Physiol. 281, R25–R30
11. Sugimoto, R., Kumagai, Y., Nakai, Y., and Ishii, T. (2005) Free Radic. Biol. Med. 38, 388–395[CrossRef][Medline] [Order article via Infotrieve]
12. Inoue, K., Takano, H., Hiyoshi, K., Ichinose, T., Sadakane, K., Yanagisawa, R., Tomura, S., and Kumagai, Y. (2007) Eur. Respir. J. 29, 259–267[Abstract/Free Full Text]
13. Taguchi, K., Fujii, S., Yamano, S., Cho, A. K., Kamisuki, S., Nakai, Y., Sugawara, F., Froines, J. R., and Kumagai, Y. (2007) Free Radic. Biol. Med. 43, 789–799[CrossRef][Medline] [Order article via Infotrieve]
14. Chung, M. Y., Lazaro, R. A., Lim, D., Jackson, J., Lyon, J., Rendulic, D., and Hasson, A. S. (2006) Environ. Sci. Technol. 40, 4880–4886[Medline] [Order article via Infotrieve]
15. Cho, A. K., Di Stefano, E., Ying, Y., Rodriguez, C. E., Schmitz, D. A., Kumagai, Y., Miguel, A. H., Eiguren-Fernandez, A., Kobayashi, T., Avol, E., and Froines, J. R. (2004) Aerosol Sci. Technol. 38, 68–81[CrossRef]
16. Valavanidis, A., Fiotakis, K., Vlahogianni, T., Papadimitriou, V., and Pantikaki, V. (2006) Environ. Chem. 3, 118–123[CrossRef]
17. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Chem. Res. Toxicol. 13, 135–160[CrossRef][Medline] [Order article via Infotrieve]
18. Brunmark, A., and Cadenas, E. (1989) Free Radic. Biol. Med. 7, 435–477[CrossRef][Medline] [Order article via Infotrieve]
19. Kikuno, S., Taguchi, K., Iwamoto, N., Yamano, S., Cho, A. K., Froines, J. R., and Kumagai, Y. (2006) Toxicol. Appl. Pharmacol. 210, 47–54[CrossRef][Medline] [Order article via Infotrieve]
20. Tonks, N. K., Diltz, C. D., and Fischer, E. H. (1988) J. Biol. Chem. 263, 6722–6730[Abstract/Free Full Text]
21. Haj, F. G., Markova, B., Klaman, L. D., Bohmer, F. D., and Neel, B. G. (2003) J. Biol. Chem. 278, 739–744[Abstract/Free Full Text]
22. Urbanek, R. A., Suchard, S. J., Steelman, G. B., Knappenberger, K. S., Sygowski, L. A., Veale, C. A., and Chapdelaine, M. J. (2001) J. Med. Chem. 44, 1777–1793[CrossRef][Medline] [Order article via Infotrieve]
23. Kar, S., Lefterov, I. M., Wang, M., Lazo, J. S., Scott, C. N., Wilcox, C. S., and Carr, B. I. (2003) Biochemistry 42, 10490–10497[CrossRef][Medline] [Order article via Infotrieve]
24. Zheng, J., and Hammock, B. D. (1996) Chem. Res. Toxicol. 9, 904–909[CrossRef][Medline] [Order article via Infotrieve]
25. Kumagai, Y., Lin, L. Y., Hiratsuka, A., Narimatsu, S., Suzuki, T., Yamada, H., Oguri, K., Yoshimura, H., and Cho, A. K. (1994) Mol. Pharmacol. 45, 359–365[Abstract]
26. Laemmli, U. K. (1970) Nature 227, 680–685[CrossRef][Medline] [Order article via Infotrieve]
27. Kyhse-Andersen, J. (1984) J. Biochem. Biophys. Methods 10, 203–209[CrossRef][Medline] [Order article via Infotrieve]
28. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
29. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1992) Short Protocols in Molecular Biology, pp. 8.1–8.19, Green Publishing Associates/Jhon Wiley & Sons, Inc., New York
30. Riddles, P. W., Blakeley, R. L., and Zerner, B. (1983) Methods Enzymol. 91, 49–60[Medline] [Order article via Infotrieve]
31. Barford, D., Flint, A. J., and Tonks, N. K. (1994) Science 263, 1397–1404[Abstract/Free Full Text]
32. Abdelmohsen, K., Gerber, P. A., von Montfort, C., Sies, H., and Klotz, L. O. (2003) J. Biol. Chem. 278, 38360–38367[Abstract/Free Full Text]
33. Hansen, S. K., Cancilla, M. T., Shiau, T. P., Kung, J., Chen, T., and Erlanson, D. A. (2005) Biochemistry 44, 7704–7712[CrossRef][Medline] [Order article via Infotrieve]
34. Andersen, J. N., Mortensen, O. H., Peters, G. H., Drake, P. G., Iversen, L. F., Olsen, O. H., Jansen, P. G., Andersen, H. S., Tonks, N. K., and Moller, N. P. (2001) Mol. Cell Biol. 21, 7117–7136[Free Full Text]
35. Bonner, J. C. (2002) Am. J. Physiol. 283, L528–L530
36. Wu, W., Samet, J. M., Ghio, A. J., and Devlin, R. B. (2001) Am. J. Physiol. 281, L483–L489

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Kobayashi, L. Li, N. Iwamoto, Y. Nakajima-Takagi, H. Kaneko, Y. Nakayama, M. Eguchi, Y. Wada, Y. Kumagai, and M. Yamamoto The Antioxidant Defense System Keap1-Nrf2 Comprises a Multiple Sensing Mechanism for Responding to a Wide Range of Chemical Compounds Mol. Cell. Biol., January 15, 2009; 29(2): 493 - 502. [Abstract] [Full Text] [PDF]

				C. Fila, C. Metz, and P. van der Sluijs Juglone Inactivates Cysteine-rich Proteins Required for Progression through Mitosis J. Biol. Chem., August 1, 2008; 283(31): 21714 - 21724. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Supplemental Data All Versions of this Article: 282/46/33396    most recent M705224200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwamoto, N. Articles by Kumagai, Y. Search for Related Content PubMed PubMed Citation Articles by Iwamoto, N. Articles by Kumagai, Y. Social Bookmarking                      What's this?